AVX001 Gel (skin cancer)

Based on the findings of the COAK study, Coegin Pharma plans to broaden the clinical development of AVX001 to basal cell carcinoma (BCC). Coegin Pharma has begun preparations for a Phase IIa trial with the aim to initiate the trial in the first half of 2023. The trial is a proof-of-concept study designed to confirm the positive safety and tolerability findings from the COAK study, and to investigate the clinical efficacy of AVX001 in the treatment of basal cell carcinoma. In the planned Phase IIa trial, Coegin Pharma will make use of valuable documentation and experience from the COAK study, where the digitalisation of patient recruitment and study implementation allowed the study to be carried out quickly and cost-effectively. Through further development of AVX001 in a Phase IIa trial in basal cell carcinoma, the company is addressing two major disease indications with AVX001, where better treatment options are urgently needed. The goal is to develop a drug for both actinic keratosis and basal cell carcinoma, which is believed to maximise the value of the drug candidate significantly.